Đăng xuất
Operable node-negative breast cancer, Operable node-positive breast cancer
Adult: As adjuvant treatment in combination with doxorubicin and cyclophosphamide: 75 mg/m2 once every 3 weeks for 6 cycles, given via IV infusion over 1 hour. Premedicate with oral corticosteroid for 3 days starting 1 day prior to infusion. Primary granulocyte-colony stimulating factor (G-CSF) may be used as prophylaxis to reduce the risk of haematological toxicities. For patients with node-negative cases, treatment must be restricted to patients eligible to receive chemotherapy based on internationally established criteria for primary treatment of early breast cancer. Dose reduction, dosing interruption, or discontinuation may be required if severe or febrile neutropenia, severe cutaneous reactions, severe peripheral neuropathy, or other severe adverse reactions occur (refer to detailed product guidelines).
Intravenous
Locally advanced breast cancer, Metastatic breast cancer
Adult: As 1st-line treatment in combination with doxorubicin, or in combination with capecitabine after failure of cytotoxic chemotherapy: 75 mg/m2 once every 3 weeks via IV infusion over 1 hour. As monotherapy after failure of previous chemotherapy: 60-100 mg/m2 once every 3 weeks via IV infusion over 1 hour. Premedicate with oral corticosteroid for 3 days starting 1 day prior to infusion. Dose reduction, dosing interruption, or discontinuation may be required if severe or febrile neutropenia, severe cutaneous reactions, severe peripheral neuropathy, or other severe adverse reactions occur (refer to detailed product guidelines).
Intravenous
Locally advanced non-small cell lung carcinoma, Metastatic non-small cell lung carcinoma
Adult: In combination with cisplatin in chemotherapy-naive patients with unresectable cases, or as monotherapy after failure of prior platinum-based chemotherapy: 75 mg/m2 once every 3 weeks via IV infusion over 1 hour. Premedicate with oral corticosteroid for 3 days starting 1 day prior to infusion. Dose reduction, dosing interruption, or discontinuation may be required if severe or febrile neutropenia, severe cutaneous reactions, severe peripheral neuropathy, or other severe adverse reactions occur (refer to detailed product guidelines).
Intravenous
Gastro-oesophageal junction adenocarcinoma, Metastatic gastric adenocarcinoma
Adult: In combination with cisplatin and fluorouracil for patients who have not received prior chemotherapy: 75 mg/m2 every 3 weeks via IV infusion over 1 hour. Premedicate with oral corticosteroid for 3 days starting 1 day prior to infusion. Granulocyte-colony stimulating factor (G-CSF) may be used as prophylaxis to reduce the risk of haematological toxicities. Dose reduction, dosing interruption, or discontinuation may be required if severe or febrile neutropenia, severe cutaneous reactions, severe peripheral neuropathy, or other severe adverse reactions occur (refer to detailed product guidelines).
Intravenous
Metastatic castration-resistant prostate cancer
Adult: In combination with prednisone or prednisolone: 75 mg/m2 once every 3 weeks via IV infusion over 1 hour. Premedicate with oral dexamethasone at 12 hours, 3 hours, and 1 hour prior to infusion. Dose reduction, dosing interruption, or discontinuation may be required if severe or febrile neutropenia, severe cutaneous reactions, severe peripheral neuropathy, or other severe adverse reactions occur (refer to detailed product guidelines).
Intravenous
HER2-overexpressing metastatic breast cancer
Adult: In combination with trastuzumab for patients who have not previously received chemotherapy: 100 mg/m2 once every 3 weeks via IV infusion over 1 hour. Premedicate with oral corticosteroid for 3 days starting 1 day prior to infusion. Dose reduction, dosing interruption, or discontinuation may be required if severe or febrile neutropenia, severe cutaneous reactions, severe peripheral neuropathy, or other severe adverse reactions occur (refer to detailed product guidelines).
Intravenous
Locally advanced squamous cell carcinoma of the head and neck
Adult: As induction treatment in combination with cisplatin and fluorouracil: 75 mg/m2 once every 3 weeks for 3 cycles (followed by chemoradiotherapy) or for 4 cycles (followed by radiotherapy alone). Doses are given via IV infusion over 1 hour. Premedicate with oral corticosteroid for 3 days starting 1 day prior to infusion. Granulocyte-colony stimulating factor (G-CSF) may be used as prophylaxis to reduce the risk of haematological toxicities. Dose reduction, dosing interruption, or discontinuation may be required if severe or febrile neutropenia, severe cutaneous reactions, severe peripheral neuropathy, or other severe adverse reactions occur (refer to detailed product guidelines).
